Epistatic interaction between adiponectin and survivin gene polymorphisms in endometrial carcinoma

Pathology Research and Practice

Volumn 211, Issue 4, 2015, Pages 293-297

  Aminimoghaddam, Soheila ^a   Shahrabi Farahani, Maryam ^b   Mohajeri Tehrani, Mohammadreza ^b   Amiri, Parvin ^b   Fereidooni, Forozande ^c   Larijani, Bagher ^b   Shafiee, Gita ^b   Amoli, Mahsa M ^b  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adiponectin; Endometrial cancer; Polymorphism; Survivin

Indexed keywords

ADIPONECTIN; SURVIVIN; ADIPOQ PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ADIPONECTIN GENE; ADULT; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA BASE COMPOSITION; DNA EXTRACTION; ENDOMETRIUM CARCINOMA; EPISTASIS; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IRANIAN PEOPLE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVIN GENE; UPREGULATION; AGED; CROSS-SECTIONAL STUDY; ENDOMETRIUM TUMOR; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RISK;

ADIPONECTIN; AGED; CROSS-SECTIONAL STUDIES; ENDOMETRIAL NEOPLASMS; EPISTASIS, GENETIC; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 84925181739     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2014.11.012     Document Type: Article

References (40)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Xu W.H., Matthews C.E., Xiang Y.B., Zheng W., Ruan Z.X., Cheng J.R., Gao Y.T., Shu X.O. Effect of adiposity and fat distribution on endometrial cancer risk in Shanghai women. Am. J. Epidemiol. 2005, 161:939-947.
3. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 2004, 4:579-591.
4. Gornick M.C., Rennert G., Moreno V., Gruber S.B. Adiponectin gene and risk of colorectal cancer. Br. J. Cancer 2011, 105:562-564.
5. Kelesidis I., Kelesidis T., Mantzoros C.S. Adiponectin and cancer: a systematic review. Br. J. Cancer 2006, 94:1221-1225.
6. Korner A., Pazaitou-Panayiotou K., Kelesidis T., Kelesidis I., Williams C.J., Kaprara A., Bullen J., Neuwirth A., Tseleni S., Mitsiades N., Kiess W., Mantzoros C.S. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J. Clin. Endocrinol. Metab. 2007, 92:1041-1048.
7. Dieudonne M.N., Bussiere M., Dos Santos E., Leneveu M.C., Giudicelli Y., Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem. Biophys. Res. Commun. 2006, 345:271-279.
8. Dhillon P.K., Penney K.L., Schumacher F., Rider J.R., Sesso H.D., Pollak M., Fiorentino M., Finn S., Loda M., Rifai N., Mucci L.A., Giovannucci E., Stampfer M.J., Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2011, 20:2618-2627.
9. Kaklamani V.G., Wisinski K.B., Sadim M., Gulden C., Do A., Offit K., Baron J.A., Ahsan H., Mantzoros C., Pasche B. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA 2008, 300:1523-1531.
10. Zhou W., Liu Y., Zhong D.W. Adiponectin (ADIPOQ) rs2241766 G/T polymorphism is associated with risk of cancer: evidence from a meta-analysis. Tumour Biol. 2013, 34:493-504.
11. Chen X., Xiang Y.B., Long J.R., Cai H., Cai Q., Cheng J., Wen W., Gao Y.T., Zheng W., Shu X.O. Genetic polymorphisms in obesity-related genes and endometrial cancer risk. Cancer 2012, 118:3356-3364.
12. Altieri D.C. Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J. Cell Biochem. 2004, 92:656-663.
13. Melet A., Song K., Bucur O., Jagani Z., Grassian A.R., Khosravi-Far R. Apoptotic pathways in tumor progression and therapy. Adv. Exp. Med. Biol. 2008, 615:47-79.
14. Zahedi P., Aminimoghaddam S., Sayahpour F.A., Haghpanah V., Amiri P., Fereidoni F., Mahrampour E., Larijani B., Tavakkoly-Bazzaz J., Amoli M.M. Association of survivin gene polymorphism with endometrial cancer. Int. J. Gynecol. Cancer 2012, 22:35-37.
15. Dan H.C., Jiang K., Coppola D., Hamilton A., Nicosia S.V., Sebti S.M., Cheng J.Q. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 2004, 23:706-715.
16. Sommer K.W., Schamberger C.J., Schmidt G.E., Sasgary S., Cerni C. Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene 2003, 22:4266-4280.
17. Dalamaga M., Diakopoulos K.N., Mantzoros C.S. The role of adiponectin in cancer: a review of current evidence. Endocr. Rev. 2012, 33:547-594.
18. Announcements FIGO stages 1988 revision. Gynecol. Oncol. 1989, 35:125-127.
19. Shi S.R., Cote R.J., Wu L., Liu C., Datar R., Shi Y., Liu D., Lim H., Taylor C.R. DNA. extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: heating under the influence of pH. J. Histochem. Cytochem. 2002, 50:1005-1011.
20. Mostaan L.V., Tabari A., Amiri P., Ashtiani M.K., Mahdkhah A., Yazdani N., Khaniki M., Tavakkoly-Bazzaz J., Amoli M.M. Survivin gene polymorphism association with tongue squamous cell carcinoma. Genet. Test Mol. Biomark. 2013, 17:74-77.
21. Xu Y., Fang F., Ludewig G., Jones G., Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004, 23:419-429.
22. Xu L., Zhou X., Yin R. Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies. Tumour Biol. 2014, 35:1661-1669.
23. Wang X., Huang L., Xu Y., Shi Z., Wang Y., Zhang J., Wang X., Cao L., Luo H., Chen J., Liu N., Yin Y., You Y. Association between survivin -31G>C promoter polymorphism and cancer risk: a meta-analysis. Eur. J. Hum. Genet. 2012, 20:790-795.
24. Qin C., Cao Q., Li P., Ju X., Wang M., Chen J., Wu Y., Meng X., Zhu J., Zhang Z., Lu Q., Yin C. Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population. PLoS One 2012, 7:e28829.
25. Okamura K., Koike H., Sekine Y., Matsui H., Suzuki K. Survivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer. Cancer Epidemiol. 2009, 33:137-141.
26. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 2003, 3:46-54.
27. Reed J.C. The Survivin saga goes in vivo. J. Clin. Invest. 2001, 108:965-969.
28. Carvajal-Carmona L.G., Spain S., Kerr D., Houlston R., Cazier J.B., Tomlinson I. Common variation at the adiponectin locus is not associated with colorectal cancer risk in the UK. Hum. Mol. Genet. 2009, 18:1889-1892.
29. Tschritter O., Fritsche A., Thamer C., Haap M., Shirkavand F., Rahe S., Staiger H., Maerker E., Haring H., Stumvoll M. Plasma Adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003, 52:239-243.
30. Spranger J., Kroke A., Mohlig M., Bergmann M.M., Ristow M., Boeing H., Pfeiffer A.F.H. Adiponectin and protection against type 2 diabetes mellitus. Lancet Res. Lett. 2003, 361:226-228.
31. Teras L.R., Goodman M., Patel A.V., Bouzyk M., Tang W., Diver W.R., Feigelson H.S. No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol. Biomark. Prev. 2009, 18:2553-2557.
32. Rizk N.M., El-Menyar A., Marei I., Sameer M., Musad T., Younis D., Farag F., Basem N., Al-Ali K., Al Suwaidi J. Association of adiponectin gene polymorphism (+T45G) with acute coronary syndrome and circulating adiponectin levels. Angiology 2013, 64:257-265.
33. Rahal O.M., Simmen R.C. Paracrine-acting adiponectin promotes mammary epithelial differentiation and synergizes with genistein to enhance transcriptional response to estrogen receptor beta signaling. Endocrinology 2011, 152:3409-3421.
34. Gritsko T., Williams A., Turkson J., Kaneko S., Bowman T., Huang M., Nam S., Eweis I., Diaz N., Sullivan D., Yoder S., Enkemann S., Eschrich S., Lee J.H., Beam C.A., Cheng J., Minton S., Muro-Cacho C.A., Jove R. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 2006, 12:11-19.
35. Miyazaki T., Bub J.D., Uzuki M., Iwamoto Y. Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem. Biophys. Res. Commun. 2005, 333:79-87.
36. Diaz N., Minton S., Cox C., Bowman T., Gritsko T., Garcia R., Eweis I., Wloch M., Livingston S., Seijo E., Cantor A., Lee J.H., Beam C.A., Sullivan D., Jove R., Muro-Cacho C.A. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin. Cancer Res. 2006, 12:20-28.
37. Papapetropoulos A., Fulton D., Mahboubi K., Kalb R.G., O'Connor D.S., Li F., Altieri D.C., Sessa W.C. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J. Biol. Chem. 2000, 275:9102-9105.
38. Asanuma H., Torigoe T., Kamiguchi K., Hirohashi Y., Ohmura T., Hirata K., Sato M., Sato N. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res. 2005, 65:11018-11025.
39. Cong L., Gasser J., Zhao J., Yang B., Li F., Zhao A.Z. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2. Endocr. Relat. Cancer 2007, 14:713-720.
40. Kim K.Y., Baek A., Hwang J.E., Choi Y.A., Jeong J., Lee M.S., Cho D.H., Lim J.S., Kim K.I., Yang Y. Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res. 2009, 69:4018-4026.